Peripheral arterial disease and chronic heart failure: a dangerous mix

被引:0
作者
Sally C. Inglis
Adriana Hermis
Sajad Shehab
Phillip J. Newton
Sara Lal
Patricia M. Davidson
机构
[1] University of Technology Sydney,Centre for Cardiovascular and Chronic Care, Faculty of Nursing, Midwifery and Health
[2] University of Technology Sydney,School of Medical and Molecular Sciences, Faculty of Science
来源
Heart Failure Reviews | 2013年 / 18卷
关键词
Chronic heart failure; Peripheral arterial disease; Outcomes; Prevalence; Function; Mortality;
D O I
暂无
中图分类号
学科分类号
摘要
Chronic heart failure (CHF) is associated with a high comorbidity burden, adverse impact on quality of life and high health care utilisation. Peripheral arterial disease (PAD) and CHF share many risk, pathophysiological and prognostic features, and each has been associated with increased morbidity and mortality. PAD often goes undetected, and yet in spite of the availability of screening tools, this is not commonly considered in CHF care. A review of the electronic databases Medline, CINAHL and Cochrane CENTRAL was undertaken using the MeSH terms peripheral arterial disease, peripheral vascular disease, intermittent claudication and heart failure to identify studies examining the prevalence and clinical outcomes of coexisting PAD in patients with CHF. Five studies were identified. There are limited data describing the impact of PAD on CHF outcomes. As PAD may contribute to decreased capacity to exercise and other self-care behaviours, identifying those at risk and providing appropriate therapy are important. Based on this review, patients who are smokers and those with diagnosed coronary heart disease and diabetes should be targeted for the screening of PAD.
引用
收藏
页码:457 / 464
页数:7
相关论文
共 210 条
  • [1] Jones WS(2011)Effect of peripheral arterial disease on functional and clinical outcomes in patients with heart failure (from HF-ACTION) Am J Cardiol 108 380-384
  • [2] Clare R(2010)Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the controlled rosuvastatin multinational trial in heart failure trial (CORONA) Eur J Heart Fail 12 698-705
  • [3] Ellis SJ(2010)Effects of peripheral arterial disease on outcomes in advanced chronic systolic heart failure Circ Heart Fail 3 118-124
  • [4] Mills JS(2009)The prevalence of peripheral arterial disease in patients with heart failure by race and ethnicity Congest Heart Fail 16 118-121
  • [5] Fischman DL(2011)Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction Clin Res Cardiol 100 755-764
  • [6] Kraus WE(2004)Prevalence of and risk factors for peripheral arterial disease in the United States Circulation 110 738-743
  • [7] Inglis SC(2008)Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication Circulation 117 2484-2491
  • [8] McMurray JV(2007)Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) Eur J Vasc Endovasc Surg 33 S1-S75
  • [9] Böhm M(2009)Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective german reach registry cohort Clin Res Cardiol 98 249-256
  • [10] Schaufelberger M(2006)Medical treatment of peripheral arterial disease JAMA 295 547-553